Canada markets closed

Lucid Diagnostics Inc. (LUCD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.0000+0.1200 (+6.38%)
At close: 04:00PM EST
2.0600 +0.06 (+3.00%)
After hours: 06:13PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.8800
Open1.9000
Bid1.8200 x 1100
Ask1.9200 x 1400
Day's Range1.8200 - 2.0000
52 Week Range1.5100 - 7.4650
Volume36,681
Avg. Volume63,522
Market Cap78.215M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.5380
Earnings DateNov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.22
  • Business Wire

    Lucid Diagnostics Presents Real-World EsoCheck Data at the American Association for Cancer Research

    NEW YORK, December 01, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today announced that Suman M. Verma, M.D., Ph.D., Lucid’s Chief Scientific Officer, presented real-world data on its EsoCheck® Cell Collection Device ("EsoCheck") at the American Association for Cancer Research’s ("AACR") Special Conference: Precision Prevention, Early Detect

  • Business Wire

    PAVmed Provides Business Update and Third Quarter 2022 Financial Results

    NEW YORK, November 15, 2022--PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the three and nine months ended September 30, 2022.

  • Business Wire

    Lucid Diagnostics Provides Business Update and Third Quarter 2022 Financial Results

    NEW YORK, November 14, 2022--Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed"), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2022.